News | Interventional Radiology | February 09, 2016

First Patient Treated With LC Bead LUMI Radiopaque Embolic Bead

Collaborative treatment supported by Philips Live Image Guidance brings new tools to interventional radiologists and oncologists to help treat liver cancer and enhanced patient care

BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer

February 9, 2016 — BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI in conjunction with Philips Live Image Guidance. The treatment targeted a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world, and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer. Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next-generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI, in order to deliver their treatment with more confidence when treating liver cancer.

“The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patient’s treatment and hopefully improve targeting accuracy,” said Bradford Wood, M.D., director of the NIH Center for Interventional Oncology and chief of interventional radiology. “It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI in combination with dedicated Philips 2-D X-ray and 3-D CBCT [cone beam computed tomography] image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information.”

By enabling visualization of beads during an embolization procedure, LC Bead LUMI will help embolization technology achieve its full potential. LC Bead LUMI has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. The device, supported by Philips Live Image Guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

LC Bead LUMI was cleared for clinical use in the United States in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead.

BTG and Philips will showcase their advancements in interventional oncology at the upcoming symposium on Clinical Interventional Oncology (CIO), taking place Feb. 6 – 7 in Hollywood, Fla.

For more information: www.btg-im.com, www.philips.com

Related Content

Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
Mentice and Siemens Healthineers Integrate VIST Virtual Patient With Artis Icono Angiography System
Technology | Interventional Radiology | June 24, 2019
Siemens Healthineers and Mentice AB announced the collaboration to fully integrate Mentice’s VIST Virtual Patient into...
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
Merit Medical Acquires Brightwater Medical Inc.
News | Interventional Radiology | June 19, 2019
Merit Medical Systems Inc. announced it has acquired Brightwater Medical Inc., based in Temecula, Calif. Brightwater...
ControlRad Announces FDA Clearance and Launch of ControlRad Trace
Technology | Radiation Dose Management | May 23, 2019
ControlRad Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its ControlRad...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Philips Launches IntraSight Interventional Applications Platform
Technology | Interventional Radiology | May 20, 2019
Philips announced the launch of the new IntraSight interventional applications platform. The secure, application-based...
360 Photos | Angiography | May 17, 2019
This is a view inside one of the 11 cath labs at ...